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A B S T R A C T
The significance of HDL concentration in assessing cardiovascular risk has been rec-
ognized over 20 years ago by the Framingham study and it has been subsequently con-
firmed by other studies and meta-analyses. However, LDL cholesterol has been as-
signed the cardinal role in cardiovascular (CV) risk management because of its clear 
etiopathogenic correlation with CV outcome and the efficacy of the drugs used to ma-
nipulate its levels in order to change patient prognosis. It is rather recently that HDL 
has gained the scientific interest once again, with the development of novel agents 
exhibiting a remarkable ability in raising HDL levels. In this article we comment on 
the re-emerging role of HDL manipulation with regard to the new CETP inhibitors, 
under the light of the recent data obtained from large trials assessing their efficacy 
and safety. 
I N T R O D U C T I O N
The significance of high density lipoprotein (HDL) cholesterol levels in cardiovas-
cular disease (CVD) progression and outcome has been recognized at least since 1977 
based on the results of the Framingham study.1 More recent data from a meta-analysis 
of four studies with a total number of over 15000 patients have shown that a 1 mg/dl 
increase of HDL-C levels is associated with a 2–3% decreased CVD risk.2 However, 
the etiopathogenic correlations are not as well established as between low density 
lipoprotein (LDL) cholesterol and CVD risk, because in the latter case the relation-
ship is considered causal. On the contrary, HDL levels vary according to numerous 
other factors, which have been confirmed independent risk factors of cardiovascular 
disease such as male gender, smoking, obesity, physical exercise, diabetes, systemic 
inflammation and hypertriglyceridemia.3-8 The difficulty of inducing increases in HDL 
and the limiting side effects of the conventional drugs used for this purpose have 
rendered HDL a non-primary target of lipid modulation efforts. However, the devel-
opment of new agents with marked efficacy in raising HDL levels, have provided new 
pharmacological potential. The cholesteryl ester transfer protein (CETP) inhibitors 
torcetrapib, dalcetrapib and anacetrapib have gained the scientific interest. However, 
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torcetrapid has already been abandoned due to an increase in 
mortality among the patients randomized to it, but the other 
two agents are still under investigation with the preliminary 
results being encouraging and the results of on-going large 
clinical trials eagerly awaited.
H D L  B I O C H E M I C A L  R O L E  A N D  C E T P 
I N H I B I T I O N 
HDL can act as an acceptor of cellular cholesterol from 
peripheral cells that is mediated by lipid transporter mol-
ecules such as ATP-binding cassette transporter A1 and G1 
(ABCA1 and ABCG1) and scavenger receptor B-I (SR-BI). 
Subsequently, lipids are delivered to the liver for ultimate 
excretion into the feces. Moreover, HDL can deliver choles-
terol to (V) LDL, which can be taken up via the LDL receptor 
(LDLr) pathway. The key enzyme catalyzing this procedure 
is cholesteryl ester transfer protein (CETP).9,10 In terms of 
pure biochemistry this procedure may seem quite clarified. 
Physiology, however, is more complicated. Some studies show 
a proportional correlation between HDL concentration and 
fecal sterol excretion, while others do not.11-14 Interventions 
aiming at increasing HDL concentration also elicited incon-
sistent results. The infusion of reconstituted HDL increased 
sterol excretion while CETP inhibition had a neutral effect 
despite the marked increase in HDL levels.15,16 
The most important contribution of HDL in atheroprotec-
tion probably lies in the first step of the reverse cholesterol 
transport pathway (RCT), which is the lipid transport from 
lipid-laden macrophages within the vessel wall to the HDL 
particles. The capacity of HDL to induce cholesterol ef-
flux from the macrophages provides a measure to evaluate 
HDL-modulating interventions. Again, several trials provide 
inconsistent results. Torcetrapib has been shown to increase 
that capacity;17 yet Chirinos et al demonstrated that patients 
with recurrent cardiovascular events had unexpectedly high 
cholesterol acceptor capacity.18 Studies examining the relation 
between cholesterol efflux and atherosclerosis progression 
assessed by carotid intima-media thickness (IMT) measure-
ment and coronary angiography have also produced conflicting 
results.19,20 
Although its role is not yet fully elucidated, HDL exerts 
beneficial vascular effects by decreasing lipopolysaccharide-
induced adhesion of leukocytes to human endothelial cells and 
inhibiting the expression of endothelial adhesion molecules, 
LDL-induced monocyte transmigration, LDL oxidation and 
reactive oxygen species formation.21-26 Moreover, it has been 
shown to protect endothelial cells from apoptosis induced by 
mildly oxidized LDL and it exerts antithrombotic and anti-
platelet action via the inhibition of coagulation factors and 
enhancement of nitric oxide production.27-29 
For these reasons and on the basis of established epidemio-
logical evidence, despite the current discrepancies observed in 
the results of several trials, manipulation of HDL still remains 
an attractive pharmacological aim and a field of continuous 
and considerable research. Recently the AIM-HIGH trial did 
not show any clinical benefit in patients with low HDL and 
high triglyceride concentration who had achieved the target 
level of LDL and received nicotinic acid on top of statin treat-
ment, despite the favorable change in their lipid profile.30 
This much awaited trial was recently terminated by the US 
National Heart, Lung, and Blood Institute due to futility. 
No separation of outcome curves between treatment groups 
could be discerned. 
Furthermore, the induction of HDL increase has proven 
difficult. Statins produce a slight effect on HDL levels and nico-
tinic acid has a rather limited use because its side effects impair 
patient compliance significantly. Cholesteryl ester transfer 
protein (CETP) inhibitors have emerged as exceptionally ef-
ficient agents with regards to raising HDL levels, although their 
clinical usefulness is still under debate. CETP promotes the 
transfer of cholesteryl esters from HDL to other lipoproteins, 
such as very low density lipoproteins and intermediate-density 
lipoproteins and their exchange for triglycerides; subsequently, 
these cholesterol-enriched lipoproteins can be cleared by the 
LDL receptor in hepatocytes. However, this pathway may 
not be perfectly efficient and thus these apo-B particles may 
remain in the blood and promote atherogenesis. On the other 
hand, the triglyceride-rich HDL can undergo lipolysis by the 
hepatic lipase. It has thus been suggested that CETP inhibition 
will preserve HDL particles, raise HDL cholesterol levels and 
decrease LDL cholesterol levels.31 
The first clues regarding the effect of CETP activity on 
HDL levels came from Japan, where CETP mutations are 
relatively common. The less the enzyme function, the higher 
the HDL concentration; however, this did not necessarily cor-
relate with cardiovascular (CV) outcome. At least for certain 
mutations, the relationship between risk for CAD and serum 
HDL-C was U-shaped, suggesting that very high serum levels 
of HDL-C were detrimental.32,33 
Trials evaluating the relationship between CETP function 
and CV risk have also elicited conflicting results. The Women’s 
Genome Health Study, the Veterans Affairs HDL Cholesterol 
Intervention trial and a large meta-analysis of 92 trials have 
shown that the single nucleotide polymorphism Taq1B is as-
sociated with a per allele rise in HDL-C and a reduction in 
risk for myocardial infarction. Notably, the homozygous state 
for the Taq1 B2B2 genotype led to higher baseline levels of 
HDL cholesterol and a 48% lower rate of cardiovascular events 
compared to men with the B1B1 genotype.34,35 On the contrary, 
the Copenhagen City Heart Study demonstrated that the loss-
of-function polymorphism Ile405 → Val was associated with 
increased risk for CAD despite higher serum HDL-C, while the 
gain-of-function mutations A373P and R451Q correlated with 
a 36% lower risk for CAD despite the low levels of HDL.36,37 
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In the Prevention of Renal and Vascular End-Stage Disease 
study, the 629 C > A loss-of function polymorphism was as-
sociated with reduced CETP activity, increased serum HDL 
cholesterol, and increased risk for cardiovascular events.38 
Similarly, the REGRESS study, the Framingham Offspring 
Study39 and the Ludwigshafen Risk and Cardiovascular Health 
Study of German patients,40 all suggested an inverse relation-
ship between CETP activity and risk for CAD-related events. 
C L I N I C A L  T R I A L S
So far it has become obvious that the relationship between 
CETP functionality and CVD risk is not linear and a certain 
level of enzymatic activity probably exists which produces 
the most beneficial outcome. To elucidate these complicated 
and confusing data, and to provide robust clinical evidence, 
pharmacological intervention was undertaken. The first CETP 
inhibitor to be evaluated was torcetrapib which was ultimately 
tested in the ILLUMINATE trial.
I L L U M I N A T E  T R I A L
This trial evaluated torcetrapib in clinical events based on 
previous encouraging results in animal models and early phase 
studies in humans showing an impressive increase of HDL by 
60 to 100% with a contemporary decrease of LDL cholesterol 
by up to 20%, though it proved inefficient in reducing ather-
omatous burden in the coronary arteries or carotid IMT.41-44
A total of 15,000 stable patients with a history of cardio-
vascular disease or type II diabetes were randomized to ator-
vastatin plus torcetrapib 60 mg or atorvastatin alone, after a 
period of 4-10 weeks of atorvastatin pre-treatment to achieve 
LDL concentration below 100 mg/dl. The primary outcome 
was the time to death from coronary heart disease, nonfatal 
myocardial infarction, stroke or hospitalization for unstable 
angina. In the torcetrapib group, HDL cholesterol increased 
by 72.1%, while LDL cholesterol and triglycerides decreased 
by 24.9% and 9% respectively at 12 months. All these changes 
were statistically significant. However, the hazard ratio for 
the primary outcome was 1.25 in the torcetrapib group, as 
compared with the atorvastatin-only group (95% confidence 
interval [CI], 1.09 to 1.44; P = 0.001). Among the individual 
components of the composite primary endpoint, death from 
any cause was also significantly more frequent in the torce-
trapib arm. These results led to the premature termination of 
the study. The exact cause of this unexpected outcome is not 
fully elucidated. Torcetrapib induces synthesis of both aldos-
terone and cortisol in adrenal cortical cells.45 A rise in blood 
pressure, attributed mainly to increased levels of aldosterone, 
and the formation of dysfunctional or even proatherogenic 
HDL cholesterol particles are considered possible pathoge-
netic mechanisms.46 
d a l - V E S S E L  T R I A L
Under the realizations made when the results of the IL-
LUMINATE trial were published, dal-VESSEL was designed 
to investigate the effects of dalcetrapib on endothelial function, 
blood pressure, inflammatory markers, and lipid levels. A total 
of 476 patients with known coronary heart disease or at risk of 
it and who had achieved the target LDL concentration, were 
randomized in a double-blind manner to receive dalcetrapib 
600 mg/day or placebo for 36 weeks on top of standard therapy 
(including statins). The two groups were compared over a 
primary efficacy end point including the change from baseline 
of flow-mediated dilatation (%FMD) of the right brachial 
artery at 12 weeks and the 24-hour ambulatory blood pres-
sure monitoring at 4 weeks. The change of FMD at 36 weeks, 
ambulatory blood pressure monitoring at 12 and 36 weeks, 
changes in HDL-cholesterol, LDL-cholesterol, triglycerides, 
CETP activity and standard safety parameters were also as-
sessed as secondary endpoints. Measurements of FMD did not 
differ significantly between the two arms of the trial after 12 
and 36 weeks (P = 0.1764 and 0.9515, respectively). Similarly, 
ambulatory blood pressure assessment did not reveal any 
increase in the dalcetrapib receiving patients up to 36 weeks. 
Activity of CETP decreased by more than 50% in the active 
treatment group (P <0.0001), and HDL-cholesterol increased 
by 25, 27, and 31% at 4, 12, and 36 weeks respectively (P 
<0.0001). Interestingly, LDL levels did not change. Among the 
biomarkers of inflammation, oxidative stress, and coagulation 
only Lp-PLA(2) mass levels increased by 17%. The number 
of clinical events was the same in both study groups. Based on 
these results, dalcetrapib can be considered a tolerable and 
safe agent which increases HDL-cholesterol levels without 
affecting nitric oxide-dependent endothelial function, blood 
pressure, or markers of inflammation and oxidative stress.47
d a l - P L A Q U E  T R I A L
This study, included clinically stable patients with previous 
known coronary heart disease or at high risk of coronary heart 
disease (diabetes or a 10-year risk of coronary heart disease 
events >20% by Framingham Risk scoring), triglyceride con-
centrations of 400 mg/dL or lower (≤4.5 mmol/L), and PET/CT 
index of carotid or aortic arterial wall (target) to background 
(blood) ratio (TBR) of 1.6 or higher, as identified by 18F-FDG 
uptake measured by PET/CT. They received hypolipidemic 
medication other than fibrates or nicotinic acid to maximal 
tolerated dosage or that achieving LDL-cholesterol level 
below 100 mg/dl. Finally, 130 patients were randomized in a 
1:1 ratio to receive either dalcetrapib 600 mg/day or placebo 
for 24 months. The primary MRI endpoint was the change 
in total vessel area, wall area, wall thickness, and wall area/
total vessel area ratio (normalized wall index) expressed as 
absolute or percent difference, or both after 24 months. The 
same variables served as secondary endpoints when assessed 
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in 6 and 12 months. The primary PET/CT endpoint was the 
change in arterial wall 18F-FDG uptake (assessed as the TBR) 
after 6 months, a measurement assessing vascular inflamma-
tion. Biochemical indices’ change after 3, 12, and 24 months, 
such as C-reactive protein (hsCRP), lipoprotein-associated 
phospholipase A2 (Lp-PLA2), interleukin 6, soluble P-selectin 
(sP-selectin), soluble E-selectin (sE-selectin), soluble intra-
cellular adhesion molecule, soluble vascular cell adhesion 
molecule, matrix-metalloproteinase 3 and 9, myeloperoxidase, 
tissue plasminogen activator, and antigen and activity of plas-
minogen activator inhibitor 1 were also taken into account as 
complementary endpoints. Total vessel area was significantly 
reduced in the dalcetrapib group at 24 months (–4.01 mm2, 
90% CI –7.23 to –0.80, p 0.04). The other indices were not dif-
ferent. Concentrations of HDL-cholesterol increased by 31% 
and those of apolipoprotein A1 increased by 10% at 24 months 
in the dalcetrapib-receiving subjects. As far as the PET/CT 
primary end point of most-diseased-segment TBR of the index 
vessel is concerned, mean change from baseline was –0.26 (SE 
0.08) for placebo and –0.19 (SE 0.08) for dalcetrapib (p=0.51). 
Thus, no evidence of increased vascular inflammation with 
dalcetrapib compared with placebo was noticed. However, 
in the carotid arteries average most diseased-segment TBR 
was significantly reduced only in the dalcetrapib group but 
compared with placebo, this reduction was non-significant. 
In the whole study population, increases in HDL-cholesterol 
did not correlate with structural changes in the vessels as as-
sessed by MRI, while they were associated with decreases in 
TBR-assessed arterial inflammation (p=0.04). More specifi-
cally, a 4.3% reduction in most-diseased-segment TBR was 
recorded with every increase in HDL-C tertile. However, due 
to the extreme heterogeneity of the tertiles with respect to the 
therapy given, since the lowest tertiles represent patients in 
the placebo group and the highest ones lie in the dalcetrapib 
group, the relative influence of HDL levels is not possibly clari-
fied. No significant differences were reported in terms of drug 
discontinuation or adverse events between the two groups. 
In conclusion, in this trial, dalcetrapib seems to cause no 
short term harm and can possibly decrease adverse structural 
changes within the vessels by reducing vascular inflammation 
and increasing HDL-cholesterol concentrations.48
D E F I N E  T R I A L
This trial aimed at assessing the efficacy and safety of an-
acetrapib in patients already in statin therapy who had achieved 
the target LDL cholesterol levels and had HDL levels below 
60 mg/dl. The 1623 patients with known coronary heart disease 
or at high risk for coronary events (Framingham Risk score 
of >20% per 10 years) were randomized to either 100 mg of 
anacetrapib daily or placebo on top of statin administration 
and the two groups were compared with regard to percent-
age changes of LDL in 24 weeks. The change in LDL, HDL, 
non-HDL cholesterol, apolipoprotein B, and apolipoprotein 
A-I concentration at 24 and 76 weeks were also evaluated. 
The safety end point required assessment of adverse events, 
laboratory testing related to safety (hepatic biochemistry, 
electrolyte and aldosterone levels, markers of muscle damage), 
assessment of vital signs, cardiovascular outcome and death 
throughout the 76-week treatment period. The primary efficacy 
end point was met; LDL decreased from 81 mg/dl to 45 mg/
dl in the anacetrapib group, as compared with a change from 
82 mg/dl to 77 mg/dl in the placebo group which represented 
a significant 39.8% reduction (P<0.001) at 24 weeks. Similar 
results were obtained for HDL concentration which increased 
by 138.1% (41 mg/dl to 101 mg/dl compared with 40 mg/dl to 
46 mg/dl in the placebo group P<0.001). The other lipid vari-
ables showed significant improvement as well and all these 
changes were maintained until the end of the study follow-up 
at 76 weeks. The safety end points, laboratory or clinical, did 
not differ between the two groups. The exact incidences sug-
gest, through a Bayesian analysis, that there is a 94% predictive 
probability that the 25% increase in cardiovascular adverse 
events that was seen with torcetrapib will not be the case with 
anacetrapib also.49
C O N C L U S I O N
In conclusion, CETP inhibition represents the single 
most efficient way to raise significantly HDL concentration. 
However, it remains in doubt whether this biochemical modu-
lation will be translated to clinical benefit. The first agent of 
the category, torcetrapib, failed to improve prognosis; on the 
contrary it increased mortality because it promoted aldoster-
one synthesis and raised blood pressure. The novel members 
dalcetrapib and anacetrapib have demonstrated a favorable 
safety profile and hopefully they will not exert the adverse out-
come observed with their ancestor. The early studies suggest 
they improve the lipid profile with regard to both HDL and 
LDL levels, and dalcetrapib may also be efficient in terms of 
vascular atheroprotection. A large trial with clinical endpoints 
is currently being conducted (dal-OUTCOMES) and its results 
are expected to enlighten the field and determine the final 
role of CETP inhibition in cardiovascular risk management.
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